Team
DNA Repair and Uveal Melanoma (D.R.U.M)
Thematic areas of research:
Image
To top
Team
MARC-HENRI STERN
DNA Repair and Uveal Melanoma (D.R.U.M)
Our team DNA Repair and Uveal Melanoma (D.R.U.M.) was created at Institut Curie in 2001. Its goal is to understand the malignant processes involved in human cancers. More specifically, our main interests are presently (i) in genomic instabilities in breast/ovarian cancers and uveal melanoma and (ii) in genetics and genomics of uveal melanoma. Through the development of innovative bioinformatics tools and data mining efforts, as well as experimental biology, we aim to identify new predisposing factors to cancer and novel therapeutics.
Members
Image
Image
Key publications
All publications
-
Different Pigmentation Risk Loci for High-Risk Monosomy 3 and Low-Risk Disomy 3 Uveal MelanomasJNCI: Journal of the National Cancer Institute
-
-
Germline MBD4 Mutations and Predisposition to Uveal MelanomaJNCI: Journal of the National Cancer Institute
-
-
News
All news
-
Un nouveau projet d’envergure pour comprendre et combattre le mélanome uvéalL’Institut Curie a lancé en septembre dernier un projet ambitieux dans la lutte contre le mélanome uvéal, le cancer de l’œil le plus fréquent chez l’adulte. En collaboration avec le Melanoma Patients Network Europe (MPNE) et soutenu par le Secrétaire adjoint américain à la défense pour les affaires sanitaires et approuvé par le ministère américain de la Défense, le projet a pour objectifs d’identifier la prédisposition génétique, la tumorigenèse ainsi que les réponses immunitaires spécifiques à ce cancer.31/10/2023 -
Immunotherapy, a new ally against cervical cancer?Could chemoradiotherapy in combination with immunotherapy help fight cervical cancer? To start to answer the question, a team from Institut Curie conducted a phase-I clinical trial. The results, published in Nature Communications, do not simply reveal good tolerance for the treatment, but they also highlight the biomarkers predictive of its efficacy.07/09/2023 -
Response to chemotherapy: finally a biomarker for triple negative breast cancerIn triple negative breast cancer, how do we select those patients who will respond to chemotherapy with platinum salts? In Nature Communications, a team from Institut Curie makes an interesting proposal: to use the homologous recombination defect as a biomarker.25/04/2023 -
A new factor in prognosis for metastatic uveal melanomaHow can we achieve a more accurate prognosis for patients after removal of liver metastases from uveal melanoma? By using a differentiating marker, namely circulating tumor DNA. This has just been shown by a study in one of the top surgery journals, Annals of Surgery, involving Institut Curie’s medical and research teams.31/03/2023 -
Institut Curie certified as Integrated cancer research site for the third timeFollowing a call for applications launched in April 2022, Institut Curie had its integrated cancer research site project certified by France’s Institut national du cancer (Inca). Its goal is to better understand tumor recurrences in order to better prevent, detect and treat them.20/02/2023
Partners
